Market Research Report: Aranscia

Company Profile

Overview

Aranscia is a leading provider of precision medicine diagnostics and solutions based in Houston, Texas. The company specializes in molecular diagnostics, genomics, and digital-first clinical workflows. Their comprehensive offerings include diagnostic software, services, and testing innovations specifically designed to enhance patient care outcomes. The company's technology facilitates precision diagnostics in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening.

Visit [Aranscia Website](https://www.aranscia.com/) for more information.

Key Offerings

Diagnostic Software: Enabling transformative diagnostic solutions across any EMR platform.

Pharmacogenetic Testing: Supports proactive decision-making at the point of care.

Lab-Agnostic Services: Streamlines and facilitates all testing needs with a focus on patient outcomes.

Turnkey Programs: Specialized in precision oncology, infectious disease management, and genetic screening.

Leadership Team

Bryon Cipriani - President and CEO

Nearly 30 years of experience in the healthcare industry.

Dave Copas - Member, Board of Directors

Over 35 years in healthcare IT and operations.

Joe Spinelli - Chief Strategy Officer

Experience in product and corporate development.

Grattan Smith - Chief Revenue Officer

25+ years in healthcare IT, focusing on sales and business development.

H. Rey Stroube IV - CFO

30+ year career in finance.

Dr. Joel Diamond - Chief Medical Officer

Extensive clinical and technology implementation experience.

Assaf Halevy - Founder, 2bPrecise

Pioneered clinical integration and population health management platforms.

Shelly Buchman - Director, Legal and Compliance

22 years in legal, HR, and compliance roles.

Houda Hachad, PharmD, M. Res - Vice President of Clinical Operations

Active member in several pharmacogenomics working groups.

Kristine Ashcraft - President and Founder, YouScript

25+ years in precision medicine, recognized as one of the leading global voices in the field.

Dr. Burns C. Blaxall - Senior Vice President of Precision Medicine

Developed a nationally recognized program for individualized care.

Contact Information

Email: info@aranscia.com

Phone: 888-958-2298

Address: 4035 Willowbend Blvd., Suite #400, Houston, TX 77025

Competitor Profile

Competitors

Omega Therapeutics

Website: [Omega Therapeutics](https://omegatherapeutics.com/)
Overview: Omega Therapeutics is a clinical-stage biotechnology company focusing on developing programmable epigenomic mRNA medicines aimed at unprecedented control over gene regulation and cellular function.
Key Technologies:

OMEGA Platform: Combining computational genomics, machine learning, and artificial intelligence.

Epigenomic Controllers: mRNA therapeutics engineered to control gene expression pre-transcriptionally.

Leadership:

President & CEO: Mahesh Karande

Founders: Noubar Afeyan, David Berry

Founding Scientific Advisors: Dr. Rudolf Jaenisch, Dr. Richard Young

BiomeSense

Website: [BiomeSense](https://www.biomesense.com/)
Overview: BiomeSense develops integrated biosensor and bioinformatics platforms for continuous, at-home monitoring of the human microbiome.
Key Technologies:

GutLab: Continuous tracking of the gut microbiome.

MetaBiome: AI-enabled bioinformatics platform for microbiome data.

Leadership:

Co-Founder & CEO: Kevin Honaker

CTO: Dylan Nichols

Bioinformatics Lead: Yoshiki Vázquez-Baeza

Myriad Genetics

Website: [Myriad Genetics](https://myriad.com/about-myriad-genetics/)
Overview: Myriad Genetics specializes in genetic testing and precision medicine, offering molecular diagnostic products that provide actionable insights for predicting and managing human diseases.
Key Metrics:

Employees: 2,600

Annual Genetic Tests Performed: Over 1 million

Active Ordering Physicians: 42,000+

Microba Life Sciences

Website: [Microba](https://microba.com/)
Overview: A precision microbiome company that uses advanced technology for gut microbiome analysis and therapeutic discovery.
Key Technologies:

Analysis Platform: Comprehensive solution for microbiome analysis.

Discovery Platform: Globally unique databank for microbiome discovery.

Therapeutic Platform: Platform for generating microbial therapeutic leads.

Leadership:

CEO: Luke Reid

Folio3

Website: [Folio3](https://folio3.com/)
Overview: A software development company providing digital transformation services including web and mobile app development, cloud solutions, ERP systems, and e-commerce integrations.
Services:

AI-based software solutions

ERP systems

Digital Health solutions

Leadership:

Various notable clients and extensive customer testimonials.

Strategic Insight

Aranscia faces competition from diverse companies focusing on precision medicine, genetic testing, microbiome analysis, and digital transformation solutions. Companies like Omega Therapeutics and Microba Life Sciences excel in the precision and personalized medicine sectors, especially in microbiome and genetic domains. Competitors such as Folio3 are expanding digital health solutions, adding a competitive layer in software and data analytics.

Aranscia should focus on: